Regimen A
Sponsors
Northwestern University, Medical University of South Carolina, GlaxoSmithKline, Pearl Therapeutics, Inc.
Conditions
CancerChronic Obstructive Pulmonary DiseaseHematological MalignanciesLymphoma
Phase 1
An Open Label Study to Examine the Effects of a High-Fat Meal and Particle Size on the Pharmacokinetics of Orally Administered GSK2118436 in Subjects With BRAF Mutation Positive Tumor
CompletedNCT01231568
Start: 2010-10-21End: 2011-05-13Updated: 2017-11-14
A Randomized, Open-label, Single-dose, Single-center, Crossover Study in Healthy Subjects to Assess the Relative Bioavailability of PT010
CompletedNCT03311373
Start: 2017-10-17End: 2017-12-15Updated: 2020-06-11
Phase 2
Doxorubicin Hydrochloride Liposome and Rituximab With Combination Chemotherapy in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Burkitt-Like Lymphoma
CompletedNCT00392990
Start: 2007-02-06End: 2013-05-28Updated: 2019-10-15
Allogeneic Hematopoietic Stem Cell Transplantation With Reduced Intensity Pre-transplant Conditioning for the Treatment of High-risk Hematological Malignancies (V3)
TerminatedNCT01139164
Start: 2010-06-30End: 2015-12-31Updated: 2018-07-11